Immune receptor signaling, aging and autoimmunity

Advances in Experimental Medicine and Biology

Volumn 640, Issue , 2008, Pages 312-324

  Larbi, Anis ^a   Fülöp, Tamas ^b   Pawelec, Graham ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

AGING; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNE SYSTEM; KNOWLEDGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SENESCENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; ANIMAL; CELL MEMBRANE; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

AGING; ANIMALS; AUTOIMMUNITY; HUMANS; MEMBRANE MICRODOMAINS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 58149358477     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09789-3_21     Document Type: Review

References (82)

1. Crews DE, Zavotka S. Aging, disability and frailty: Implications for universal design. J Physiol Anthropol 2006; 25:113-8.
2. Wiet SG. Future of caring for an aging population: Trends, technology and caregiving. Stud Health Technol Inform 2005; 118:220-30.
3. Webster RG. Immunity to influenza in the elderly. Vaccine 2000; 18:1686-9.
4. Levy R. Costs and benefits of pharmaceuticals: The value equation for older Americans. Care Manag J 2002; 3:135-42.
5. Pawelec G, Adibzadeh M, Solana R et al. The T-cell in the ageing individual. Mech Ageing Dev 1997; 93:35-45.
6. Pawelec G. Immunosenescence and human longevity. Biogerontology 2003; 4:167-70.
7. Makinodan T. Nature of the dechne in antigen-induced hmnoral immunity with age. Mech Ageing Dev 1980; 14:165-72.
8. Aspinall R Andrew D. Thymic involution in aging. J CUn Immunol 2000; 20:250-6.
9. Pawelec G, Akbar A, Caruso C et al. Human immunosenescence: Is it infectious? Immunol Rev 2005; 205:257-68.
10. Linton PJ, Haynes L, Tsui L et al. From naive to effector-alterations with aging. Immunol Rev 1997; 160:9-18.
11. Vallejo AN, Brandes JC, Weyand CM et al. Modulation of CD28 expression: Distinct regulatory pathways during activation and replicative senescence. J Immunol 1999; 162:6572-9.
12. Dennett NS, Barcia RN, McLeod JD. Age associated decline in CD25 and CD28 expression correlate with an increased susceptibility to CD95 mediated apoptosis in T-cells. Exp Gerontol 2002; 37:271-83.
13. Sandmand M, Bruunsgaard H, Kemp K et al. Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans? Clin Exp Immunol 2002; 127:107-14.
14. Ef& os RB, Dagarag M, Spaulding C et al. The role of CD8+ T-cell replicative senescence in human aging. Immunol Rev 2005; 205:147-57.
15. Fulop T, Larbi A, Wikby A et al. Dysregulation of T-cell function in the elderly: Scientific basis and clinical implications. Drugs Aging 2005; 22:589-603.
16. van Dijk-Hard I, Soderstrom I, Feld S et al. Age-related impaired affinity maturation and differential D-JH gene usage in human VH6-expressing B lymphocytes from healthy individuals. Eur J Immunol 1997; 27:1381-6.
17. Miller JP, Allman D. Linking age-related defects in B lymphopoiesis to the aging of hematopoietic stem cells. Semin Immunol 2005; 17:321-9.
18. Mocchegiani E, Malavolta M. NK and NKT-cell functions in immunosenescence. Aging Cell 2004; 3:177-84.
19. DelaRosa O, Tarazona R, Casado JG et al. Valpha24+ NKT-cells are decreased in elderly humans. Exp Gerontol 2002; 37:213-7.
20. Sebastian C, Espia M, Serra M et al. MacrophAging: A cellular and molecular review. Immunobiology 2005; 210:121-6.
21. Fulop T, Larbi A, Douziech N et al. Signal transduction and functional changes in neutrophils with aging. Aging Cell 2004; 3:217-26.
22. Franceschi C, Bonafe M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908:244-54.
23. Garcia GG, Miller RA. Single-cell analyses reveal two defects in peptide-specific activation of naive T-cells from aged mice. J Immunol 2001; 166:3151-7.
24. Fulop Jr T, Gagne D, Goulet AC et al. Age-related impairment of p561ck and ZAP-70 activities in human T lymphocytes activated through the TcR/CD3 complex. Exp Gerontol 1999; 34:197-216.
25. Kawanishi H. Activation of calcium (Ca)-dependent protein kinase C in aged mesenteric lymph node T and B-cells. Immunol Lett 1993; 35:25-32.
26. Whisler RL, Newhouse YG, Bagenstose SE. Age-related reductions in the activation of mitogen-activated protein kinases p44mapk/ERKl and p42mapk/ERK2 in human T-cells stimulated via ligation of the T-cell receptor complex. Cell Immunol 1996; 168:201-10.
27. Mustelin T, Rahmouni S, Bottini N et al. Role of protein tyrosine phosphatases in T-cell activation. Immunol Rev 2003; 191:139-47.
28. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T-cell activation. Immunol Cell Biol 1997; 75:430-45.
29. Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human T-cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT Cell Immunol 1996; 169:185-95.
30. Ponnappan S, Uken-Trebilcock G, Lindquist M et al. Tyrosine phosphorylation-dependent activation of NFkappaB is compromised in T-cells from the elderly. Exp Gerontol 2004; 39:559-66.
31. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387:569-72.
32. Janes PW, Ley SC, Magee AL Aggregation of lipid rafts accompanies signaling via the T-cell antigen receptor. J Cell Biol 1999; 147:447-61.
33. Hancock JF. Lipid rafts: Contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006; 7:456-62.
34. Kusumi A, Suzuki K. Toward understanding the dynamics of membrane-raft-based molecular interactions. Biochim Biophys Acta 2005; 1746:234-51.
35. Balamuth F, Brogdon JL, Bottomly K. CD4 raft association and signaling regulate molecular clustering at the immunological synapse site. J Immunol 2004; 172:5887-92.
36. Manes S, Viola A. Lipid rafts in lymphocyte activation and migration. Mol Membr Biol 2006; 23:59-69.
37. Huber LA, Xu QB, Jurgens G et al. Correlation of lymphocyte lipid composition membrane microviscosity and mitogen response in the aged. Eur J Immunol 1991; 21:2761-5.
38. Simons K, Ehehalt R. Cholesterol, lipid rafts and disease. J Clin Invest 2002; 110:597-603.
39. Garcia GG, Miller RA. Single-cell analyses reveal two defects in peptide-specific activation of naive T-cells from aged mice. J Immunol 2001; 166:3151-7.
40. Larbi A, Douziech N, Khalil A et al. Effects of methyl-beta-cyclodextrin on T lymphocytes lipid rafts with aging. Exp Gerontol 2004; 39:551-8.
41. Larbi A, Douziech N, Dupuis G et al. Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes. J Leukoc Biol 2004; 75:373-81.
42. Kovacs B, Parry RV, Ma Z et al. Ligation of CD28 by its natural ligand CD86 in the absence of TCR stimulation induces lipid raft polarization in human CD4 T-cells. J Immunol 2005; 175:7848-54.
43. Resh MD. Membrane targeting of lipid modified signal transduction proteins. Subcell Biochem 2004; 37:217-32.
44. Hundt M, Tabata H, Jeon MS et al. Impaired activation and localization of LAT in anergic T-cells as a consequence of a selective palmitoylation defect. Immunity 2006; 24:513-22.
45. Larbi A, Dupuis G, Khalil A et al. Differential role of lipid rafts in the functions of CD4-I- and CD8+ human T lymphocytes with aging. Cell Signal 2006; 18:1017-30.
46. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004; 378:281-92.
47. Douglass AD, Vale RD. Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T-cells. Cell 2005; 121:937-50.
48. Grauby-Heywang C, Turlet JM. Behavior of GM3 ganglioside in lipid monolayers mimicking rafts or fluid phase in membranes. Chem Phys Lipids 2006; 139:68-76.
49. Langhorst MF, Reuter A, Stuermer CA. Scaffolding microdomains and beyond: The function of reggie/ flotillin proteins. Cell Mol Life Sci 2005; 62:2228-40.
50. Henel G, Singh K, Cui D et al. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin- like receptors. Blood 2006; 107:4449-57.
51. Ouyang Q, Wagner WM, Voehringer D et al. Age-associated accumulation of CMV-specific CD8+ T-cells expressing the inhibitory killer cell lectin-like receptor Gl (KLRGl). Exp Gerontol 2003; 38:911-20.
52. Fortin CF, Larbi A, Lesur O et al. Impairment of SHP-1 down-regulation in the lipid rafts of human neutrophils under GM-CSF stimulation contributes to their age-related, altered functions. J Leukoc Biol 2006; 79:1061-72.
53. Rui L, Vinuesa CG, Blasioli J et al. Resistance to CpG DNA-induced autoimmunity through tolerogenic B-cell antigen receptor ERK signaling. Nat Immunol 2003; 4:594-600.
54. Samuels J, Ng YS, Coupillaud C et al. Impaired early B-cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005; 201:1659-67.
55. Rifas L, Arackal S. T-cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthritis Rheimi 2003; 48:993-1001.
56. Brennan F, Foey A. Cytokine regulation in RA synovial tissue: Role of T-cell/macrophage contactdependent interactions. Arthritis Res 2002; 4: S177-82.
57. Romagnoli P, Strahan D, Pelosi M et al. A potential role for protein tyrosine kinase p56(lck) in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness. Int Immunol 2001; 13:305-12.
58. Cope AP. Studies of T-cell activation in chronic inflammation. Arthritis Res 2002; 4:S197-211.
59. Lewis DE, Merched-Sauvage M, Goronzy JJ et al. Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription. J Biol Chem 2004; 279:29130-8.
60. Bruunsgaard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 2002; 13:389-91.
61. Pavon EJ, Munoz P, Navarro MD et al. Increased association of CD38 with lipid rafts in T-cells from patients with systemic lupus erythematosus and in activated normal T-cells. Mol Immunol 2006; 43:1029-39.
62. Hadrup SR, Strindhall J, Kollgaard T et al. Longitudinal studies of clonally expanded CD8 T-cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T-cells in the very elderly. J Immunol 2006; 176:2645-53.
63. Nambiar MP, Mitchell JP, Ceruti RP et al. Prevalence of T-cell receptor zeta chain deficiency in systemic lupus erythematosus. Lupus 2003; 12:46-51.
64. Juang YT, Wang Y, Solomon EE et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115:996-1005.
65. Krishnan S, Nambiar MP, Warke VG et al. Alterations in lipid raft composition and dynamics contribute to abnormal T-cell responses in systemic lupus erythematosus. J Immunol 2004; 172:7821-31.
66. Jury EC, Kabouridis PS, Flores-Borja F et al. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113:1176-87.
67. Sibilia J. Novel concepts and treatments for autoimmune disease: Ten focal points. Joint Bone Spine 2004;71:511-7.
68. Shimpi S, Chauhan B, Shimpi P. Cyclodcxtrins: Application in different routes of drug administration. Acta Pharm 2005; 55:139-56.
69. GroU AH, Wood L, Rodcn M et al. Safety, pharmacokinetics and pharmacodynamics of cyclodcxtrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46:2554-63.
70. Johnson JL, He Y, Jain A et al. Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid. AAPS PharmSciTech 2006; 7:E18.
71. Ghorab MM, Abdel-Salam HM, El-Sayad MA et al. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailabiUty evaluation. AAPS Pharm Sci Tech 2004; 5:e.59.
72. Loftsson T, Masson M. Cyclodcxtrins in topical drug formulations: Theory and practice. Int J Pharm 2001; 225:15-30.
73. Magee T, Seabra MC. Fatty acylation and prenylation of proteins: What s hot in fat. Curr Opin Cell Biol 2005; 17:190-6.
74. Garcia GG, Miller RA. Age-related defects in CD4+ T-cell activation reversed by glycoprotein endopeptidasc. Eur J Immunol 2003; 33:3464-72.
75. Cavaglicri CR, Nishiyama A, Fernandes LC et al. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci 2003; 73:1683-90.
76. Zeyda M, Staffler G, Horejsi V et al. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T-cell signaling by polyunsaturated fatty acids. J Biol Chem 2002; 277:28418-23.
77. Stulnig TM, Berger M, Sigmund T et al. Polyunsaturated fatty acids inhibit T-cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol 1998; 143:637-44.
78. Larbi A, Grenier A, Frisch F et al. Acute in vivo elevation of intravascular triacylglycerol lipolysis impairs peripheral T-cell activation in humans. Am J Clin Nutr 2005; 82:949-56.
79. Caldcr PC. n-3 fatty acids, inflammation and immunity-Relevance to postsurgical and critically ill patients. Lipids 2004; 39:1147-61.
80. Roberts SB, Rosenberg I. Nutrition and aging: Changes in the regulation of energy metabolism with aging. Physiol Rev 2006; 86:651-67.
81. Ouyang Q, Wagner WM, Wikby A et al. Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: Contribution to the immune risk phenotype? Eur Cytokine Netw 2002; 13:392-4.
82. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 2002; 41:27-65.